The FDA has approved a new indication for Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. The Juvéderm Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest approval marks their fifth approved indication in the US, according to Allergan Aesthetics, an AbbVie company.
Juvéderm Voluma XC is the first filler to receive US FDA approval for the augmentation of the chin region. This approval marks the second indication for the product, which was previously approved by the FDA in 2013 for cheek augmentation to correct age-related mid-face volume deficit. Juvéderm Voluma XC is currently the number one product in the Juvéderm portfolio in the US and lasts up to two years with optimal treatment for cheek augmentation.
"Within my practice, I've seen a growing demand for patients looking to achieve more balanced symmetry in the face. During facial assessments, most patients don't realize that chin augmentation is another component to achieving the facial harmony they desire," says Dee Anna Glaser, MD, dermatologist in St. Louis and clinical trial investigator. "This approval is a truly exciting milestone for providers as it signals another paradigm shift in the way we are able to approach a facial consultation. I am excited to educate patients that we have a safe and predictable non-surgical treatment option to address their concern."
In the US pivotal study, Juvéderm Voluma XC was shown to be safe and effective for augmentation of the chin, with the majority of patients reporting high satisfaction throughout the 1-year follow-up.
"When assessing facial anatomy, the chin is a critical component to facial balance, yet it is often overlooked. Due to its distinct gel properties and product profile, Juvéderm Voluma XC is uniquely suitable to address this need," says Carrie Strom, Senior Vice President, AbbVie, and President, Global Allergan Aesthetics. "It's always rewarding when we can offer a safe and effective non-surgical alternative to patients. Addressing chin contour and shape is another way we are moving the market forward through our commitment to continued innovation."
Since 2018, all clinical trials for the Allergan Aesthetics portfolio have included participants reflective of a diverse patient population and demographics, including varying genders, ages, races, and ethnicities.